Patents by Inventor Rohan Mendonca

Rohan Mendonca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
    Patent number: 9604984
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: March 28, 2017
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wei Yuen
  • 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160237086
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Applicant: Genentech, Inc.
    Inventors: Mark Edward ZAK, Nicholas Charles RAY, Simon Charles GOODACRE, Rohan MENDONCA, Terry KELLAR, Yun-Xing CHENG, Wei LI, Po-Wei YUEN
  • 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
    Patent number: 9346815
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 24, 2016
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wai Yuen
  • 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20150336962
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: May 22, 2015
    Publication date: November 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wai Yuen
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20150152117
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 4, 2015
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu
  • Pyrazolopyrimidine JAK inhibitor compounds and methods
    Patent number: 8999998
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: April 7, 2015
    Assignee: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark Zak, Aihe Zhou, Bing-Yan Zhu
  • Tricyclic heterocyclic compounds, compositions and methods of use thereof
    Patent number: 8461328
    Abstract: The invention provides novel compounds of formula I having the general formula: wherein R1, R2, R3, X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: June 11, 2013
    Assignee: Genentech, Inc.
    Inventors: Srinivasan Babu, Phillippe Bergeron, Peter Dragovich, Hazel Joan Dyke, Paul Gibbons, Stefan Gradl, Emily Hanan, Christopher Hurley, Tony Johnson, Michael Koehler, Janusz Kulagowski, Sharada Labadie, Joseph Lyssikatos, Rohan Mendonca, Rebecca Pulk, Stuart Ward, Bohdan Waszkowycz, Mark Zak
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120190665
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: July 2, 2010
    Publication date: July 26, 2012
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark Zak, Aihe Zhou, Bing-Yan Zhu
  • TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20110201593
    Abstract: The invention provides novel compounds of formula I having the general formula: wherein R1, R2, R3, X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.
    Type: Application
    Filed: January 11, 2011
    Publication date: August 18, 2011
    Applicant: Genentech, Inc.
    Inventors: Srinivasan Babu, Phillippe Bergeron, Peter Dragovich, Hazel Joan Dyke, Paul Gibbons, Stefan Gradl, Emily Hanan, Christopher Hurley, Tony Johnson, Michael Koehler, Janusz Kulagowski, Sharada Labadie, Joseph Lyssikatos, Rohan Mendonca, Rebecca Pulk, Stuart Ward, Bohdan Waszkowycz, Mark Zak